Please assess the completion status of the following clinical trial:

Trial Title: South Australian Meningococcal B Vaccine Herd Immunity Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* South Australian secondary school students in years 10, 11, and 12 in 2017~* Written parental consent for those under the age of 18~* Written student consent assent for those under the age of 18 (or if 18 years old and older consent for themselves)~* Available at school for at least the first pharyngeal swab and willing to comply with study procedures~Exclusion Criteria:~1. Previous anaphylaxis following any component of Bexsero vaccine~2. Previous receipt of meningococcal B vaccine (Bexsero)~3. Known pregnancy

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group A (Type: ACTIVE_COMPARATOR): Students within schools randomised to group A will receive two doses of licensed 4CMenB vaccine after baseline oropharyngeal swab with an interval of 1 to 2 months between doses, with the first dose given at the baseline visit in 2017.
- Group B (Type: NO_INTERVENTION): Students within schools randomised to group B will receive the licensed 4CMenB vaccine following completion of baseline and 12 month oropharyngeal swab in 2018.

Based on this trial design, predict the completion outcome and termination type (if applicable).